menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Monitoring Soluble HER2 Levels in Patients with Metastatic Breast Cancer

HER2/neu-positive tumors account for approximately 20% of all breast cancers and these tumors carry poor prognosis. In HER2/neu positive breast can...

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    HER2/neu-positive tumors account for approximately 20% of all breast cancers and these tumors carry poor prognosis. In HER2/neu positive breast cancer, HER2 receptor is believed to be the main driving force responsible for tumor cell proliferation, metastatic potential and poor survival. Accordingly, therapeutic targeting of HER2/neu has the potential benefit to offset the signaling process initiated by the HER2 over-expression, thus reversing the malignant features of these tumors. Agents targeting HER2 have been shown to be associated with improvement in response rate, disease free, and overall survival.

    Join us as Dr. Edith Perez discusses the data regarding the incidence of metastatic breast cancer in younger aged women and the appropriate counseling strategies to increase patient awareness of the role of HER2 monitoring.

     

  • Disclosure of Conflicts of Interest

    Faculty:   
    Edith A. Perez, MD
    Deputy Director at Large, Mayo Clinic Cancer Center
    Group Vice Chair, Alliance for Clinical Trials in Oncology
    Serene M. and Frances C. Durling Professor of Medicine
    Mayo Clinic
    Jacksonville, FL

    Disclosure of Conflicts of Interest: TOPEC and Omnia Education assess conflict of interest with its faculty, planners, authors and reviewers of CME activities. If conflicts of interest are identified for anyone who is in a position to control content, the conflicts are thoroughly vetted and resolved in part by the use of independent reviewers who review content for fair balance, scientific objectivity of studies utilized in the activity and patient care recommendations. TOPEC and Omnia Education are committed to providing their learners with high quality, unbiased and state-of-the-art education.

    The following faculty have reported real or apparent conflicts of interest that have been resolved:

    • Edith A. Perez, MD has nothing to disclose.

    The following reviewers/planners/authors have reported real or apparent conflicts of interest that have been resolved:

    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nirupama Mulherkar, PhD has nothing to disclose.
    • Sean T. Saunders, CCMEP has nothing to disclose.
    • Edward Sauter, MD, PhD has nothing to disclose.
    • Robert S. Schneider has nothing to disclose.
  • Target Audience

    This activity has been designed to meet the educational needs of the practicing Breast Oncologist, Oncology Nurse, General Oncologist, Obstetrician and Gynecologist, Family Physician, Internal Medicine Physician, Physician Assistant and Clinical Nurse Practitioner.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the data regarding the incidence of metastatic breast cancer 
    • Define the role of HER2 monitoring in HER2 + patients with metastatic breast cancer
    • Identify appropriate patient counseling strategies to raise patient awareness of the role of HER2 monitoring
  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. (TOPEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be available for immediate download at www.reachmd.com.

  • Provider(s)/Educational Partner(s)

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Nuclea.

  • Terms of Use

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ReachMD you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Instructions

    There are no fees for participating in and receiving CME credit for this activity. During the period of Febuary 5, 2015, through February 5, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) listen to the full content of the activity and reflect upon its teachings; 3) successfully complete the post-test with a passing score and the evaluation at the end of the activity.

    Participants who successfully complete the activity, post test and evaluation will have a statement of credit made available immediately.

  • Disclaimer

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither Omnia nor TOPEC recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Omnia or TOPEC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • System Requirements

    ReachMD requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.